13 March 2018
The Russian government adopted the action plan (roadmap) for the Development of Biotechnology and Genetic Engineering in 2018 – 2020.
The plan aims at developing domestic demand, manufacturing and exports of biotech products, and building institutional environment in order to modernize the technology base of the industry through mass introduction of biotech methods and products.
It provides for further expansion of production potential and cooperation in the area of biomedicine and biopharmaceuticals, agricultural and industrial biotechnology, bioenergetics, forest and environmental biotechnology, and genetic engineering.
By 2020, 2 common use production centers licensed for manufacturing biomedical cell products will be established to conduct R&D and pre-clinical studies of biomedical cell products.
The number of medical institutions accredited for clinical trials of biomedical cell products will be increased from 5 to 50.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024